StemCells announces HuCNS-SC product positive Phase I/II interim data
The Phase I/II trial, which transplanted first cohort including three patients with a dose of 20 million cells at the thoracic site of injury having no neurological function,
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).
EP-101, an inhalation solution formulation of glycopyrrolate, a long-acting muscarinic antagonist, delivered by an investigational eFlow nebulizer, demonstrated a statistically significant improvement in lung function compared to placebo